Cholangiocarcinoma

Specialized care for bile duct cancer, including surgical options, chemotherapy, and targeted therapy.

Back to All Treatments
Cholangiocarcinoma

Cholangiocarcinoma

Solid Tumors

Overview

Cholangiocarcinoma is a rare but aggressive cancer of bile ducts. Treatment depends on location (intrahepatic, perihilar, or distal), resectability, and molecular characteristics. Early detection and complete surgical resection offer best outcomes.

When to Consult

Upon diagnosis of bile duct cancer, jaundice, unexplained weight loss, abdominal pain, or suspicious imaging findings.

What to Bring

CT/MRI scans, ERCP reports, biopsy results, CA 19-9 and CEA blood tests, genetic testing results (IDH1, FGFR2), and liver function tests.

Risk Factors

Primary sclerosing cholangitis (PSC)
Liver fluke infection (Opisthorchis, Clonorchis)
Age (risk increases with age)
Chronic liver disease and cirrhosis
Hepatitis B or C infection
Bile duct abnormalities (choledochal cysts)
Inflammatory bowel disease
Hepatolithiasis (bile duct stones)
Thorotrast exposure (historical)
Obesity and metabolic syndrome
Diabetes
Smoking
Alcohol abuse

Causes

Chronic inflammation of bile ducts
Genetic mutations (IDH1, IDH2, FGFR2, BAP1)
DNA damage from chronic inflammation
Bile stasis and irritation
Epigenetic changes
Bile duct cell transformation
Environmental toxins
Parasitic infections

Treatment Options

Surgical Resection

Complete surgical removal of tumor and affected bile ducts. Options include partial hepatectomy for intrahepatic, Whipple procedure for distal, or complex biliary reconstruction for perihilar tumors. Requires experienced hepatobiliary surgeon.

Liver Transplantation

For selected patients with perihilar cholangiocarcinoma meeting specific criteria. Combined with neoadjuvant chemoradiation protocol.

Biliary Drainage

ERCP or PTC to place stents and relieve jaundice. Important for symptom relief and preparation for treatment.

Gemcitabine/Cisplatin

Standard first-line chemotherapy for advanced cholangiocarcinoma. Combination therapy showing improved survival compared to gemcitabine alone.

FOLFOX Chemotherapy

5-FU, leucovorin, and oxaliplatin. Second-line option after gemcitabine/cisplatin. Also used as adjuvant therapy after surgery.

Targeted Therapy

Ivosidenib (IDH1 inhibitor) for IDH1-mutated tumors. Pemigatinib or infigratinib (FGFR2 inhibitors) for FGFR2 fusion-positive tumors. Based on molecular profiling.

Immunotherapy

Pembrolizumab for MSI-high or dMMR cholangiocarcinoma. Durvalumab combined with chemotherapy showing promise. Clinical trials ongoing.

Radiation Therapy

External beam radiation, often combined with chemotherapy (chemoradiation). May be used before surgery (neoadjuvant), after surgery (adjuvant), or for locally advanced disease.

Radioembolization (Y90)

Internal radiation therapy using Yttrium-90 microspheres for intrahepatic cholangiocarcinoma. Delivered via hepatic artery.

Photodynamic Therapy

Light-activated therapy combined with photosensitizing agent. Used for palliation in selected cases of unresectable disease.

Need Treatment?

Schedule a consultation to discuss treatment options for Cholangiocarcinoma .